Last reviewed · How we verify
MADALENA ASSOCIATION — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
MADALENA ASSOCIATION (MADALENA ASSOCIATION) — EMS. MADALENA is a fixed-dose combination product developed by EMS, likely containing multiple active pharmaceutical ingredients to address a specific therapeutic indication.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MADALENA ASSOCIATION TARGET | MADALENA ASSOCIATION | EMS | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MADALENA ASSOCIATION CI watch — RSS
- MADALENA ASSOCIATION CI watch — Atom
- MADALENA ASSOCIATION CI watch — JSON
- MADALENA ASSOCIATION alone — RSS
Cite this brief
Drug Landscape (2026). MADALENA ASSOCIATION — Competitive Intelligence Brief. https://druglandscape.com/ci/madalena-association. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab